GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is investing in Syndivia's ADC, fueling industry buzz for the promising anti-tumor modality.
The acquisition is worth £268m.
The gold standard of business intelligence.
GSK's move combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author's summary: GSK buys Syndivia's ADC for £268m.
More News
- LPD searches for motor vehicle theft suspect
- Lululemon Joins NFL Roster, Chasing a Comeback Season
- Annual Old Town Gazebo 'Day of the Dead' Event Cancelled
- UO’s celebration of Indigenous lives - Daily Emerald
- Monday Morning Watch | Week of Oct. 27, 2025 - BirminghamWatch
- #EyeOnMelissa: Hurricane Melissa forecast to make landfall within 24 hours - Jamaica Observer
- #EyeOnMelissa: Holness urges residents to stay away from Sandy Gully as hurricane approaches - Jamaica Observer
- Dear ASEAN Leaders: Trumpism Is Not A Temporary Phenomenon. Here’s Why?
- Queer Issues are Human Issues - The McGill Daily
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids